Pharmaceuticals and Healthcare Reports China Dyslipidemia Market | Page 2

More so than in any other market, the statins dominated Chinese dyslipidemia drugs sales in the
2013 base year, contributing 84% to the total market share, reflecting sales of $1.7 billion in total
sales.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the
purchase.
Scope
- Overview of Dyslipidemia including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting China Dyslipidemia
market.
Request a Sample Copy of This Report @
http://www.radiantinsights.com/research/dyslipidemia-china-drug-forecast-and-
market-analysis-to-2023/request-sample
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
Dyslipidemia.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in China.
See More Reports of This Category by Radiant Insights @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Follow Us: